E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 diabetes mellitus |
Type 2 diabetes mellitus |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 diabetes mellitus |
type 2 diabetes mellitus - type 2 suikerziekte |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study the effects of gDCA on postprandial GLP-1 secretion, inflammation responses and hyperlipidemia in healthy lean male subjects and male T2D patients. The primary objective of phase 1 is to determine safety of long-term gDCA administration in healthy volunteers.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to evaluate the effect of gDCA and ezetimibe on cholesterol elimination assessed as total faecal sterol concentration and plasma lipid profile/composition and the effect of different formulations on the gDCA bioavailability. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Ability to provide informed consent
- Age: 18 years or older at the time of signing the informed consent
- Male
Specific inclusion criteria for the healthy lean subject group:
- BMI between 18,5-25 kg/m2 or BMI between 25 and 30 kg/m2 with a waist circumference between between 79 cm and 94 cm
- HOMA-IR index: ≤ 2.0 (measured as fasting insulin (pmol/L) x fasting glucose (mmol/L)) / 135)
Specific inclusion criteria for the type 2 diabetes mellitus (T2D) patient group:
- T2D treated with diet and/or medication only (medication not changed in the past 3 months)
- HbA1c 53-64 mmol/mol
- BMI above 25 kg/m2
|
|
E.4 | Principal exclusion criteria |
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Use of medication that interferes with bile acid metabolism (colesevelam, colestimide, ursodeoxycholic acid).
- Diabetes treatment with dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists or insulin
- Hypercholesterolemia treatment with statins or fibrates unless on a stable dose for at least 3 months prior to screening
- Use of nicotinic acid or derivates of nicotinic acid within 4 weeks prior to screening
- Use of other drugs such as the following: vitamin K antagonists, ciclosporine, antacids containing aluminium hydroxide or aluminium oxide
- Cholecystectomy
- Gastro-intestinal disorders, including gallstone disease
- Nefropathy checked by blood chemistry (creatinine, eGFR)
- Liver disease checked by blood chemistry (ASAT, ALAT, GGT, AF, bilirubin)
- Weight increase or decrease >10% in previous 3 months
- Alcohol use >3 units/day
- Tobacco use
- XTC, cannabis, cocaine or opioids abuse
- Likely to leave the study before its completion
- Participation in other intervention studies
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase 1
The first phase of the study will be a pilot study where we investigate the metabolism and safety of long-term administration of gDCA compared to long-term administration of gDCA formulated in enteric-coated capsules (enteric-coated gDCA). In the past no safety study is performed or published investigating the metabolism of prolonged administration of (enteric-coated) glycine conjugated gDCA. Therefore we will include 20 healthy male volunteers in this phase. Ten subjects will receive 10 mg/kg/day gDCA for 30 days, the other group (N=10) will receive 10 mg/kg/day enteric-coated gDCA for 30 days. Subjects undergo a MMT at day 1, day 15 and day 30 in the AMC. After the last subject completed the study, the data will be analyses in the laboratory and discussed by the DSMB. After advise of the DSMB the project team will decide on phase 2.
Phase 2
At the second phase we include 10 T2D male patients. The 10 T2D patients will receive 10 mg/kg/day gDCA or enteric-coated gDCA. The dosage and which form of gDCA (normal or enteric-coated) will be based on the results of the pilot study (phase 1) regarding safety. Subjects undergo a MMT at day 1, day 15 and day 30 in the AMC.
Phase 3
In the third (final) phase we want to include 10 T2D male patients. The 10 T2D patients receive 10 mg/kg/day (enteric-coated) gDCA and 20 mg ezetimibe per day for 30 days. Subjects undergo a MMT at day 1, day 15 and day 30 in the AMC.
The safety of long term administration of (enteric-coated) gDCA will be established in the pilot study by the appearance of (S)AE’s (phase 1).
The effect of gDCA and enteric-coatedenteric-coated gDCA treatment (phase 1 and 2) on:
- GLP-1 and insulin levels (expressed as (incremental) AUC)
- Inflammatory responses (IL-ß, IL-6, TNF-α and leukocyte differentiation)
- Postprandial hyperlipidaemia (LDL-C, HDL-C, triglycerides, ApoB, ApoA1)
The effect of (enteric-coated) gDCA in combination with ezetimibe (phase 3) on:
- Postprandial hyperlipidaemia (LDL-C, HDL-C, triglycerides, ApoB, ApoA1)
- Cholesterol elimination assessed as total faecal sterol concentration (faecal neutral sterol concentration (FNS) + faecal bile acid concentration)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Visit 1: Day 1: baseline mixed meal test
Visit 2: Day 15: second mixed meal test
Visit 3: Day 31: third mixed meal test |
|
E.5.2 | Secondary end point(s) |
• Bile acid metabolism
- CA, CDCA, DCA, LCA and conjugates, FGF19,C4)
• Glucoregulatory and gut hormones
- Glucose, glucagon and c-peptide
• Resting energy expenditure
- Basal metabolic rate - kcal/kg/day, protein-, carbohydrate- and fat oxidation)
• Body composition (% fat mass and lean mass)
• Microbiome
- Gut microbiota composition
• Appetite
- Visual analogue scale scores + quantity of food consumed
•Total faecal sterol concentration
- FNS + faecal bile acid concentration
• Bioavailability/pharmacokinetic parameters
- Clearance, volume of distribution, absorption rate, mean residence time, elimination half-life between gDCA and enteric-coated gDCA.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Visit 1: Day 1: baseline mixed meal test + stool sampling
Visit 2: Day 15: second mixed meal test + stool sampling
Visit 3: Day 31: third mixed meal test + stool sampling |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |